Synta Pharmaceuticals Corp. ("Synta") (NASDAQ:SNTA) and Madrigal Pharmaceuticals, Inc.
The most recent short interest data has been released by the NASDAQ for the 03/15/2016 settlement date, which shows a 906,433 share decrease in total short interest for Synta Pharmaceuticals Corp , to 4,756,589, a decrease of 16.01% since 02/29/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its business strategy.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company has decided to terminate the Phase 3 GALAXY-2 trial of ganetespib and docetaxel in the second-line treatment of patients with advanced non-small...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the formation of an Expert Oncology Panel to provide guidance on research and development strategies for the Company's portfolio of novel oncology therapies.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Alan C.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that presentations related to ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development, and STA-12-8666, the...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will be participating in the FBR Second Annual Healthcare Conference on Wednesday, September 9 th in Boston.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the second quarter ended June 30, 2015 and provided a pipeline update.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its second quarter 2015 financial results on Thursday, August 6, 2015, before market open.
Investors in Synta Pharmaceuticals Corp saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SNTA options chain for the new September 18th contracts and identified the following put contract of particular interest.
Investors in Synta Pharmaceuticals Corp saw new options become available this week, for the February 2016 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the publication in this month's issue of Cancer Immunology Research of an in-depth review describing the rationale for pursuing the combination of Hsp90 and immune...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the JMP Securities Life Sciences Conference 2015 on Tuesday, June 23rd at 12:30 p.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90.
The American Society of Clinical Oncology, or ASCO, is holding the society's 51st annual meeting from May 29 to June 2 in Chicago, Illinois.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that Phase 1 clinical results from three investigator-sponsored trials evaluating ganetespib combination therapy in ALK-positive lung cancer, platinum-resistant...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3, at 11:30 a.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the first quarter ended March 31, 2015 and provided an operational update.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will report its first quarter 2015 financial results on Thursday, May 7, 2015, before market open.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced today that Chen Schor, Executive Vice President, Chief Operating Officer, has been named President, Chief Executive Officer and a Director of the Company, effective May 7,...
Shares of Synta Pharmaceuticals (SNTA) were up Thursday after the company announced presentations at the upcoming annual meeting of the American Association of Cancer Research.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster presentations related to studies with ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development, and...
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today the closing of its underwritten public offering of 25,300,000 shares of common stock, including 3,300,000 shares sold pursuant to the full exercise of the option to...
Shares of Synta Pharmaceuticals (SNTA) hit a one-year low on Tuesday after the biopharmaceutical company announced the pricing of an underwritten public offering of common stock.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that it has priced an underwritten public offering of 22,000,000 shares of its common stock at a price to the public of $1.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it has commenced an underwritten public offering of shares of its common stock.
Investors in Synta Pharmaceuticals Corp saw new options become available this week, for the November 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
